The results suggest that 4-methylumbelliferone could be a new treatment for specific BC subtypes according to estrogen receptor status by inhibiting the synthesis of HA and regulating HAS2, CD44, matrix-degrading enzymes, and inflammatory mediators (93). The gene discussed is ESR1; the disease is breast cancer.